|
1
|
Escudier B: Emerging immunotherapies for
renal cell carcinoma. Ann Oncol. 23(Suppl 8): viii35–viii40. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu S, Wu H, Nie H, Yue L, Jiang H, Xiao S
and Li Y: AIF downregulation and its interaction with STK3 in renal
cell carcinoma. PLoS One. 9:e1008242014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Srigley JR, Delahunt B, Eble JN, Egevad L,
Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, et
al: The international society of urological pathology (ISUP)
vancouver classification of renal neoplasia. Am J Surg Pathol.
37:1469–1489. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang YQ and Chen J: Predictive role of
vascular endothelial growth factor polymorphisms in the survival of
renal cell carcinoma patients. Genet Mol Res. 13:5011–5017. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flanigan RC, Campbell SC, Clark JI and
Picken MM: Metastatic renal cell carcinoma. Curr Treat Options
Oncol. 4:385–390. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Athar U and Gentile TC: Treatment options
for metastatic renal cell carcinoma: A review. Can J Urol.
15:3954–3966. 2008.PubMed/NCBI
|
|
8
|
Irani J: Sunitinib versus interferon-alpha
in metastatic renal-cell carcinoma. Prog Urol. 17:9962007.(In
French). View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toma MI, Erdmann K, Diezel M, Meinhardt M,
Zastrow S, Fuessel S, Wirth MP and Baretton GB: Lack of ephrin
receptor A1 is a favorable independent prognostic factor in clear
cell renal cell carcinoma. PLoS One. 9:e1022622014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lai EC: Micro RNAs are complementary to 3′
UTR sequence motifs that mediate negative post-transcriptional
regulation. Nat Genet. 30:363–364. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miao J, Wu S, Peng Z, Tania M and Zhang C:
MicroRNAs in osteosarcoma: Diagnostic and therapeutic aspects.
Tumour Biol. 34:2093–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ma XP, Zhang T, Peng B, Yu L and Jiang de
K: Association between microRNA polymorphisms and cancer risk based
on the findings of 66 case-control studies. PLoS One. 8:e795842013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Berezikov E, Guryev V, van de Belt J,
Wienholds E, Plasterk RH and Cuppen E: Phylogenetic shadowing and
computational identification of human microRNA genes. Cell.
120:21–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cimmino A, Calin GA, Fabbri M, Iorio MV,
Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et
al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl
Acad Sci USA. 102:13944–13949. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu X, Wu J, Li S, Hu Z, Xu X, Zhu Y, Liang
Z, Wang X, Lin Y, Mao Y, et al: Downregulation of microRNA-182-5p
contributes to renal cell carcinoma proliferation via activating
the AKT/FOXO3a signaling pathway. Mol Cancer. 13:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartels CL and Tsongalis GJ: MicroRNAs:
Novel biomarkers for human cancer. Ann Biol Clin (Paris).
68:263–272. 2010.(In French). PubMed/NCBI
|
|
18
|
Sun Y, Shen S, Liu X, Tang H, Wang Z, Yu
Z, Li X and Wu M: MiR-429 inhibits cells growth and invasion and
regulates EMT-related marker genes by targeting Onecut2 in
colorectal carcinoma. Mol Cell Biochem. 390:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bartis D, Mise N, Mahida RY, Eickelberg O
and Thickett DR: Epithelial-mesenchymal transition in lung
development and disease: Does it exist and is it important? Thorax.
69:760–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Said NA and Williams ED: Growth factors in
induction of epithelial-mesenchymal transition and metastasis.
Cells Tissues Organs. 193:85–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu W, He J, Chen D, Zhang B, Xu L, Ma H,
Liu X, Zhang Y and Le H: Expression of miR-29c, miR-93, and miR-429
as potential biomarkers for detection of early stage non-small lung
cancer. PLoS One. 9:e877802014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Miyazono K: Transforming growth
factor-beta signaling in epithelial-mesenchymal transition and
progression of cancer. Proc Jpn Acad Ser B Phys Biol Sci.
85:314–323. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: microRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
25
|
Hu X, Macdonald DM, Huettner PC, Feng Z,
El Naqa IM, Schwarz JK, Mutch DG, Grigsby PW, Powell SN and Wang X:
A miR-200 microRNA cluster as prognostic marker in advanced ovarian
cancer. Gynecol Oncol. 114:457–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie P, Xu F, Cheng W, Gao J, Zhang Z, Ge
J, Wei Z, Xu X and Liu Y: Infiltration related miRNAs in bladder
urothelial carcinoma. J Huazhong Univ Sci Technolog Med Sci.
32:576–580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nam EJI, Yoon H, Kim SW, Kim H, Kim YT,
Kim JH, Kim JW and Kim S: MicroRNA expression profiles in serous
ovarian carcinoma. Clin Cancer Res. 14:2690–2695. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sun T, Wang C, Xing J and Wu D: miR-429
modulates the expression of c-myc in human gastric carcinoma cells.
Eur J Cancer. 47:2552–2559. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun Y, Shen S, Tang H, Xiang J, Peng Y,
Tang A, Li N, Zhou W, Wang Z, Zhang D, et al: miR-429 identified by
dynamic transcriptome analysis is a new candidate biomarker for
colorectal cancer prognosis. OMICS. 18:54–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Liu Y, Wu S, Shi X, Li L, Zhao J
and Xu H: Tumor-suppressing effects of miR-429 on human
osteosarcoma. Cell Biochem Biophys. 70:215–224. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye ZB, Ma G, Zhao YH, Xiao Y, Zhan Y, Jing
C, Gao K, Liu ZH and Yu SJ: miR-429 inhibits migration and invasion
of breast cancer cells in vitro. Int J Oncol. 46:531–538.
2015.PubMed/NCBI
|
|
32
|
Wang Y, Li M, Zang W, Ma Y, Wang N, Li P,
Wang T and Zhao G: MiR-429 up-regulation induces apoptosis and
suppresses invasion by targeting Bcl-2 and SP-1 in esophageal
carcinoma. Cell Oncol (Dordr). 36:385–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dynan WS and Tjian R: The
promoter-specific transcription factor Sp1 binds to upstream
sequences in the SV40 early promoter. Cell. 35:79–87. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang WC and Hung JJ: Functional role of
post-translational modifications of Sp1 in tumorigenesis. J Biomed
Sci. 19:942012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kadonaga JT, Courey AJ, Ladika J and Tjian
R: Distinct regions of Sp1 modulate DNA binding and transcriptional
activation. Science. 242:1566–1570. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Philipsen S and Suske G: A tale of three
fingers: The family of mammalian Sp/XKLF transcription factors.
Nucleic Acids Res. 27:2991–3000. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Narayan VA, Kriwacki RW and Caradonna JP:
Structures of zinc finger domains from transcription factor Sp1.
Insights into sequence-specific protein-DNA recognition. J Biol
Chem. 272:7801–7809. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Black AR, Black JD and Azizkhan-Clifford
J: Sp1 and krüppel-like factor family of transcription factors in
cell growth regulation and cancer. J Cell Physiol. 188:143–160.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Beishline K and Azizkhan-Clifford J: Sp1
and the ‘Hallmarks of Cancer’. FEBS J. 282:224–258. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sankpal UT, Goodison S, Abdelrahim M and
Basha R: Targeting Sp1 transcription factors in prostate cancer
therapy. Med Chem. 7:518–525. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yue L, Li L, Liu F, Hu N, Zhang W, Bai X,
Li Y, Zhang Y, Fu L, Zhang X and Ye L: The oncoprotein HBXIP
activates transcriptional coregulatory protein LMO4 via Sp1 to
promote proliferation of breast cancer cells. Carcinogenesis.
34:927–935. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bonofiglio D, Qi H, Gabriele S, Catalano
S, Aquila S, Belmonte M and Andò S: Peroxisome
proliferator-activated receptor gamma inhibits follicular and
anaplastic thyroid carcinoma cells growth by upregulating
p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr Relat Cancer.
15:545–557. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yin P, Zhao C, Li Z, Mei C, Yao W, Liu Y,
Li N, Qi J, Wang L, Shi Y, et al: Sp1 is involved in regulation of
cystathionine gamma-lyase gene expression and biological function
by PI3K/Akt pathway in human hepatocellular carcinoma cell lines.
Cell Signal. 24:1229–1240. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Huang C and Xie K: Crosstalk of Sp1 and
Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth
Factor Rev. 23:25–35. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pathi S, Jutooru I, Chadalapaka G, Nair V,
Lee SO and Safe S: Aspirin inhibits colon cancer cell and tumor
growth and downregulates specificity protein (Sp) transcription
factors. PLoS One. 7:e482082012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xu Y, Zhao F, Wang Z, Song Y, Luo Y, Zhang
X, Jiang L, Sun Z, Miao Z and Xu H: MicroRNA-335 acts as a
metastasis suppressor in gastric cancer by targeting Bcl-w and
specificity protein 1. Oncogene. 31:1398–1407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang YT, Chuang JY, Shen MR, Yang WB,
Chang WC and Hung JJ: Sumoylation of specificity protein 1 augments
its degradation by changing the localization and increasing the
specificity protein 1 proteolytic process. J Mol Biol. 380:869–885.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsu TI, Wang MC, Chen SY, Yeh YM, Su WC,
Chang WC and Hung JJ: Sp1 expression regulates lung tumor
progression. Oncogene. 31:3973–3988. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Trisciuoglio D, Iervolino A, Candiloro A,
Fibbi G, Fanciulli M, ZangemeisterWittke U, Zupi G and Del Bufalo
D: Bcl-2 induction of urokinase plasminogen activator receptor
expression in human cancer cells through Sp1 activation:
involvement of ERK1/ERK2 activity. J Biol Chem. 279:6737–6745.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
DeSiervi A, Marinissen M, Diggs J, Wang
XF, Pages G and Senderowicz A: Transcriptional activation of p21
(waf1/cip1) by alkylphospholipids: Role of the mitogen-activated
protein kinase pathway in the transactivation of the human
p21(waf1/cip1) promoter by Sp1. Cancer Res. 64:743–750. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang H, Li M, Zhang R, Wang Y, Zang W, Ma
Y, Zhao G and Zhang G: Effect of miR-335 upregulation on the
apoptosis and invasion of lung cancer cell A549 and H1299. Tumour
Biol. 34:3101–3109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jiang J, Lv X, Fan L, Huang G, Zhan Y,
Wang M and Lu H: MicroRNA-27b suppresses growth and invasion of
NSCLC cells by targeting Sp1. Tumour Biol. 35:10019–10023. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mao Y, Chen H, Lin Y, Xu X, Hu Z, Zhu Y,
Wu J, Xu X, Zheng X and Xie L: microRNA-330 inhibits cell motility
by downregulating Sp1 in prostate cancer cells. Oncol Rep.
30:327–333. 2013.PubMed/NCBI
|
|
54
|
Wang F, Li Y, Zhou J, Xu J, Peng C, Ye F,
Shen Y, Lu W, Wan X and Xie X: miR-375 is down-regulated in
squamous cervical cancer and inhibits cell migration and invasion
via targeting transcription factor SP1. Am J Pathol. 179:2580–2588.
2011. View Article : Google Scholar : PubMed/NCBI
|
